
Background
Terry G. Mahn is a Principal in the Washington, D.C., office, and the Regulatory and Government Affairs Practice Group Leader. He joined the firm in 1991 and his practice is primarily before the FCC and FDA with emphasis on complex product authorizations. Mr. Mahn’s FCC practice includes all facets of spectrum allocation, wireless technology and licensing, and equipment approvals. He actively participates in domestic and international product standards development, harmonization, and compliance in the areas of radio communications, EMC, electrical, medical, and RF safety.
He is an active member of the international standards organization IEC/CISPR (International Electrochemical Commission/International Special Committee on Radio Interference) and is the U.S. Technical Advisor to CISPR Subcommittee B in charge of developing international radiofrequency interference standards for industrial, scientific, and medical devices (ISM). He has extensive knowledge on international EMC and radio regulations and spectrum allocations for many types of licensed and unlicensed communications technologies. He also represents the American National Standards Institute (ANSI) C63 Committee before the FCC and other federal agencies on various radiofrequency interference matters involving digital devices and many types of RF emitters.
His FDA practice involves pharmaceutical and medical device approvals with special emphasis on drug exclusivities and patent protection under Hatch-Waxman; “safe harbor” counseling and patent term extension applications; biosimilar approvals, brand exclusivities and patent litigation procedures under the Biologics Price Competition and Innovation Act. He also has extensive experience in the regulation of digital health, telemedicine, and wireless medical device technologies. Mr. Mahn is on the Advisory Board for the Bloomberg BNA Pharmaceutical Law and Industry Report.
What's trending with Terry
Filter by
News
September 27, 2018
Fish & Richardson Announces 13 Principals Named 2018 “Life Sciences Stars” by LMG Life Sciences
News
May 21, 2018
Fish & Richardson Announces 39 Attorneys Named “IP Stars” by Managing Intellectual Property Magazine
Event
April 15th, 2018 | 8:15 am CDT
Patent Resources Group (PRG) Spring 2018 Advanced Courses Program
Event
May 31st, 2018 | 1:00 pm EDT
Webinar: Hatch-Waxman 301
News
February 15, 2018
White House Targets Generic Exclusivity to Lower Drug Prices
News
February 7, 2018
Fish Principal Terry Mahn Testifies at U.S. Senate Special Committee on Aging, “From Joint Pain to Pocket Pain: Cost and Competition Among Rheumatoid Arthritis Therapies”
Event
January 25th, 2018 | 1:00 pm EST
Webinar: Hatch-Waxman 201
Event
April 16th, 2015 | 8:00 am EDT
Patent Resources Group (PRG) Hatch-Waxman and Biosimilars: A Total Immersion Course Encompassing Strategies for Prosecution, FDA Regulation, Post-Grant Challenge, Litigation and Appeal
Event
April 16th, 2015
Hatch-Waxman and Biosimilars: A Total Immersion Course Encompassing Strategies for Prosecution, FDA Regulation, Post-Grant Challenge, Litigation and Appeal
Event
May 19th, 2011 | 11:30 am EDT
Life Sciences Intellectual Property Summit 2011
Event
June 18th, 2014
INSIGHTS Webinar: Legal Challenges in Digital Health
Event
March 30th, 2014
Patent Resources Group PRG course: Pharma & Biotech Strategies for Patent Prosecution, Hatch-Waxman and Litigation